A rapidly expanding Ebola outbreak caused by the Bundibugyo strain — a virus subtype for which no approved vaccine or specific treatment exists — is spreading across the Democratic Republic of the Congo and into neighboring Uganda, with health authorities warning the response is falling behind the trajectory of transmission.
DR Congo Health Minister Roger Kamba stated on May 27 that approximately 1,000 suspected cases have been identified, with 101 testing positive through laboratory confirmation. Between 200 and 220 deaths are believed linked to the outbreak, 11 confirmed through laboratory testing. “We are still at the beginning of an epidemic,” Kamba said, projecting a response operation lasting four to six months.
The Africa Centres for Disease Control and Prevention reported 96 laboratory-confirmed cases and 11 confirmed deaths across the two affected countries as of May 25, with an additional 867 suspected cases and 204 suspected deaths under investigation. WHO Director-General Tedros Adhanom Ghebreyesus warned that “the epidemic in the DRC is much larger” than confirmed figures indicate, and Africa CDC chief Jean Kaseya disclosed a detection gap of silent transmission before the outbreak was officially declared on May 15.
The Bundibugyo strain is one of the rarest Ebola species known to infect humans, linked to only two prior outbreaks — Uganda in 2007 and eastern DRC in 2012. Most existing Ebola vaccines and antibody treatments were developed for the Zaire strain, responsible for the 2014–2016 West African epidemic that killed over 11,000 people. Those tools are ineffective against Bundibugyo, leaving responders reliant on surveillance, isolation, contact tracing, community engagement, and safe burials.
The absence of medical countermeasures is alarming given the virus’s lethality. Kaseya stressed that Ebola case fatality rates range from 25 to 90 percent, compared to COVID-19’s 1–2 percent. The Africa CDC has declared the outbreak a Public Health Emergency of Continental Security to strengthen regional coordination and resource mobilization.
International response is accelerating but struggling to keep pace. The United Nations released up to $60 million from its emergency response fund. MSF has deployed experienced Ebola response teams, and vaccine developers are racing to produce Bundibugyo-specific treatments — but any viable candidate remains months away. Africa CDC estimates approximately $264 million is required for response operations in DRC and Uganda, with an additional $54 million needed for preparedness across neighboring high-risk countries, though figures remain preliminary.
The DR Congo has suspended civilian passenger flights to and from Bunia, the Ituri Province capital and outbreak epicenter, while humanitarian flights continue. Kamba said the virus likely circulated before the official declaration, citing Ebola’s incubation period of up to 21 days, and that authorities have yet to identify “patient zero.” Uganda has confirmed imported cases in Kampala, and an American national working in DRC has tested positive and been transferred to Germany for care.
The structural challenges are severe: high population mobility, ongoing armed conflict in Ituri province, the M23 rebel group’s control of Goma — which hampers epidemiological surveillance and sample transport — and a laboratory network unable to detect the Bundibugyo strain locally, requiring samples to be sent to Kinshasa, approximately 2,000 kilometers away. Community resistance has also slowed the response, with some families initially attributing the illness to a “curse” rather than a virus, delaying alerts and contributing to spread.
Neighboring countries including Rwanda, Burundi, and Tanzania have stepped up surveillance and border screening. The WHO has declared the outbreak a Public Health Emergency of International Concern — its highest level of global alert — citing the scale and speed of transmission.